Numerate is an innovative player in the pharmaceutical and biotechnology landscape. Founded in 2007, the company leverages cutting-edge capabilities in AI, Machine Learning, and Life Sciences to enhance drug discovery. Through its unique computational platform, Numerate aims to predict drug behaviors, thereby streamlining the development of therapies for critical conditions like obesity, heart failure, Alzheimer's, and Huntington's disease.
Operating at the intersection of data science and medicinal chemistry, Numerate promises a more economical, expedited approach to drug development, boasting higher success rates compared to traditional methods. Although the company's headquarters remain unspecified, its impact is underscored by strategic financial backing.
The most recent funding occurred on 01 August 2019 with a $2.00M grant from the National Heart, Lung and Blood Institute. This investment not only validates Numerate's potential but also highlights confidence in its mission to transform healthcare via computational innovation.
CrystalsFirst
